The online pipeline is undergoing construction. Please refer to this PowerPoint for most up-to-date pipeline.

Trials

Trial Name Status
TBTC Study 29 published
Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis in data analysis
Celecoxib_WBA enrolling
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects all patients enrolled
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects early termination
TBTC Study 31 enrolling
NZT001 study in development
ReDEFINe study in development
HIRIF enrolling
Q203-TB-PI-US002 enrolling
Q203-TB-PI-US001 all patients enrolled
A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients enrolling
PanACEA - RUNMC - HR1 2007.23011.01 in data analysis
PanACEA-MAMS-TB-01 all patients enrolled
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection published
NC005 enrolling
TBTC Study 33/iAdhere: AdherenceC in data analysis
NC003 enrolling
STAND
Single Dose, Phase 1 published
NC001 submitted for publication
Perchlozone tablets submitted for publication
Phase 2 to Evaluate Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosi in data analysis
TBTC Study 32 enrolling
NC-003 published
TASK-001 in data analysis
Faro-WBA submitted for publication
Safety and efficacy of blocking IL-4 with pascolizumab in patients receiving standard combination therapy for pulmonary tuberculosis (TB): a randomized, double-blind, placebo-controlled, proof-of-conc enrolling
Multiple Dose, Phase 1 published
NIH: A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects published
NC002
242-12-232 enrolling
242-09-213 all patients enrolled
ACTG 5306 Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritona enrolling
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis in data analysis
Traitement du Sida submitted for publication
Phase 1 Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
ACTG 5306 Phase I Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin enrolling
Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
NC003 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) enrolling
NC001 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) submitted for publication
NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients
Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary TB all patients enrolled
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis. all patients enrolled
Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients enrolling
Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
B1171001 published
B1171002 published
242-07-204 published
TMC207-TBC211 study in development
TMC207TBC1002 published
TMC207-TIDP13-C210 study in development
TMC207-TiDP13-C209 published
TMC207-TiDP13-208 published
TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis submitted for publication
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube submitted for publication
09-0111 N01AI80024C published
SQ109-CP001 published
LMU-IMPH-SQ109-01 published
PanACEA-MAMS-TB-01 published
B1171003 published
A Phase IIa, Open Label Study to Determine the EBA, Extended EBA and Pharmacokinetic Study of LL3858 for the Treatment of Newly Diagnosed Sputum Smear-Positive Pulmonary TB study in development